Cargando…
Diet in the Treatment of Epilepsy: What We Know So Far
Epilepsy is a chronic and debilitating neurological disorder, with a worldwide prevalence of 0.5–1% and a lifetime incidence of 1–3%. An estimated 30% of epileptic patients continue to experience seizures throughout life, despite adequate drug therapy or surgery, with a major impact on society and g...
Autores principales: | Verrotti, Alberto, Iapadre, Giulia, Di Francesco, Ludovica, Zagaroli, Luca, Farello, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551815/ https://www.ncbi.nlm.nih.gov/pubmed/32872661 http://dx.doi.org/10.3390/nu12092645 |
Ejemplares similares
-
Ketogenic Diet and Epilepsy: What We Know So Far
por: D’Andrea Meira, Isabella, et al.
Publicado: (2019) -
Neuroproteomics in Epilepsy: What Do We Know so Far?
por: do Canto, Amanda M., et al.
Publicado: (2021) -
What we know so far
Publicado: (2021) -
Anabaenopeptins: What We Know So Far
por: Monteiro, Patrick Romano, et al.
Publicado: (2021) -
Autoimmune pancreatitis: What we know so far
por: Masood, Muaaz
Publicado: (2021)